{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:02:37Z","timestamp":1794632557448,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82170878"],"award-info":[{"award-number":["No. 82170878"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"crossref","award":["No. H2022307033"],"award-info":[{"award-number":["No. H2022307033"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"crossref"}]},{"name":"government-funded project for training outstanding clinical medicine talent","award":["No. ZF2023179"],"award-info":[{"award-number":["No. ZF2023179"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02723-7","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T11:21:06Z","timestamp":1744975266000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Exploring the effect of dapagliflozin on coronary inflammation in type 2 diabetes patients based on the coronary artery perivascular fat attenuation index"],"prefix":"10.1186","volume":"24","author":[{"given":"Xuehua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"2723_CR1","doi-asserted-by":"crossref","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183109119.","DOI":"10.1016\/j.diabres.2021.109119"},{"issue":"10397","key":"2723_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"regional Global","year":"2023","unstructured":"Global regional, national burden of diabetes. From 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet. 2023;402(10397):203\u201334.","journal-title":"Lancet"},{"issue":"10467","key":"2723_CR3","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","volume":"404","author":"Worldwide trends in","year":"2024","unstructured":"Worldwide trends in. Diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077\u201393.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"2723_CR4","first-page":"S14","volume":"43","author":"2","year":"2020","unstructured":"2. Classification and diagnosis of diabetes: standards of medical care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S14\u201331.","journal-title":"Diabetes Care"},{"issue":"1","key":"2723_CR5","doi-asserted-by":"publisher","first-page":"2322107","DOI":"10.1080\/20523211.2024.2322107","volume":"17","author":"MD Butt","year":"2024","unstructured":"Butt MD, Ong SC, Rafiq A, Kalam MN, Sajjad A, Abdullah M, Malik T, Yaseen F, Babar ZU. A systematic review of the economic burden of diabetes mellitus: contrasting perspectives from high and low middle-income countries. J Pharm Policy Pract. 2024;17(1):2322107.","journal-title":"J Pharm Policy Pract"},{"issue":"15","key":"2723_CR6","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1016\/j.cell.2024.06.029","volume":"187","author":"ED Abel","year":"2024","unstructured":"Abel ED, Gloyn AL, Evans-Molina C, Joseph JJ, Misra S, Pajvani UB, Simcox J, Susztak K, Drucker DJ. Diabetes mellitus-progress and opportunities in the evolving epidemic. Cell. 2024;187(15):3789\u2013820.","journal-title":"Cell"},{"key":"2723_CR7","doi-asserted-by":"crossref","unstructured":"Addendum. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020;43(Suppl. 1):S111-S134. Diabetes Care. 2020;43(8):1977\u20131978.","DOI":"10.2337\/dc20-ad08"},{"issue":"4","key":"2723_CR8","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2215\/CJN.06080616","volume":"12","author":"EJM van Bommel","year":"2017","unstructured":"van Bommel EJM, Muskiet MHA, Tonneijck L, Kramer MHH, Nieuwdorp M, van Raalte DH. SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome. Clin J Am Soc Nephro. 2017;12(4):700\u201310.","journal-title":"Clin J Am Soc Nephro"},{"issue":"5","key":"2723_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/17446651.2022.2099838","volume":"17","author":"A Shah","year":"2022","unstructured":"Shah A, Isath A, Aronow WS. Cardiovascular complications of diabetes. Expert Rev Endocrino. 2022;17(5):383\u20138.","journal-title":"Expert Rev Endocrino"},{"issue":"19","key":"2723_CR10","doi-asserted-by":"publisher","first-page":"e779","DOI":"10.1161\/CIR.0000000000000766","volume":"141","author":"SV Arnold","year":"2020","unstructured":"Arnold SV, Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE, Kosiborod M, Leiter LA, Lipska KJ, Newman JD, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American heart association. Circulation. 2020;141(19):e779\u2013806.","journal-title":"Circulation"},{"issue":"13","key":"2723_CR11","first-page":"2525","volume":"117","author":"P Libby","year":"2021","unstructured":"Libby P. Inflammation during the life cycle of the atherosclerotic plaque. Cardiovasc Res. 2021;117(13):2525\u201336.","journal-title":"Cardiovasc Res"},{"issue":"Suppl 1","key":"2723_CR12","first-page":"S98","volume":"43","author":"9","year":"2020","unstructured":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98\u2013110.","journal-title":"Diabetes Care"},{"issue":"7","key":"2723_CR13","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1007\/s00108-021-01083-0","volume":"62","author":"U Rauch-Kr\u00f6hnert","year":"2021","unstructured":"Rauch-Kr\u00f6hnert U, Landmesser U. Gliflozins-in future cardioprotective drugs? Internist. 2021;62(7):786\u201395.","journal-title":"Internist"},{"issue":"4","key":"2723_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New Engl J Med. 2019;380(4):347\u201357.","journal-title":"New Engl J Med"},{"issue":"7","key":"2723_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","volume":"12","author":"MS Usman","year":"2024","unstructured":"Usman MS, Bhatt DL, Hameed I, Anker SD, Cheng AYY, Hernandez AF, Jones WS, Khan MS, Petrie MC, Udell JA, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endo. 2024;12(7):447\u201361.","journal-title":"Lancet Diabetes Endo"},{"issue":"5","key":"2723_CR16","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.120.051675","volume":"143","author":"JJV McMurray","year":"2021","unstructured":"McMurray JJV, Wheeler DC, Stef\u00e1nsson BV, Jongs N, Postmus D, Correa-Rotter R, Chertow GM, Greene T, Held C, Hou FF, et al. Effect of Dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease. Circulation. 2021;143(5):438\u201348.","journal-title":"Circulation"},{"issue":"1","key":"2723_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12933-023-01822-7","volume":"22","author":"J Hoehlschen","year":"2023","unstructured":"Hoehlschen J, Hofreither D, Tomin T, Birner-Gruenberger R. Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review. Cardiovasc Diabetol. 2023;22(1):101.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"2723_CR18","first-page":"null","volume":"9","author":"A Krishnan","year":"2022","unstructured":"Krishnan A, Sharma H, Yuan D, Trollope AF, Chilton L. The role of epicardial adipose tissue in the development of atrial fibrillation, coronary artery disease and chronic heart failure in the context of obesity and type 2 diabetes mellitus: a narrative review. J Cardiovasc Dev Dis. 2022;9(7):null.","journal-title":"J Cardiovasc Dev Dis"},{"issue":"2","key":"2723_CR19","doi-asserted-by":"publisher","first-page":"oeab019","DOI":"10.1093\/ehjopen\/oeab019","volume":"1","author":"C Wall","year":"2021","unstructured":"Wall C, Huang Y, Le EPV, \u0106orovi\u0107 A, Uy CP, Gopalan D, Ma C, Manavaki R, Fryer TD, Aloj L, et al. Pericoronary and periaortic adipose tissue density are associated with inflammatory disease activity in Takayasu arteritis and atherosclerosis. Eur Heart J Open. 2021;1(2):oeab019.","journal-title":"Eur Heart J Open"},{"issue":"1","key":"2723_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.33549\/physiolres.933036","volume":"65","author":"Z Matloch","year":"2016","unstructured":"Matloch Z, Kotul\u00e1k T, Haluz\u00edk M. The role of epicardial adipose tissue in heart disease. Physiol Res. 2016;65(1):23\u201332.","journal-title":"Physiol Res"},{"issue":"1","key":"2723_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12933-018-0777-x","volume":"17","author":"XY Qi","year":"2018","unstructured":"Qi XY, Qu SL, Xiong WH, Rom O, Chang L, Jiang ZS. Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword. Cardiovasc Diabetol. 2018;17(1):134.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"2723_CR22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.tem.2011.07.003","volume":"22","author":"G Iacobellis","year":"2011","unstructured":"Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrin Met. 2011;22(11):450\u20137.","journal-title":"Trends Endocrin Met"},{"issue":"398","key":"2723_CR23","doi-asserted-by":"publisher","first-page":"null","DOI":"10.1126\/scitranslmed.aal2658","volume":"9","author":"AS Antonopoulos","year":"2017","unstructured":"Antonopoulos AS, Sanna F, Sabharwal N, Thomas S, Oikonomou EK, Herdman L, Margaritis M, Shirodaria C, Kampoli AM, Akoumianakis I, et al. Detecting human coronary inflammation by imaging perivascular fat. Sci Transl Med. 2017;9(398):null.","journal-title":"Sci Transl Med"},{"issue":"1","key":"2723_CR24","first-page":"81","volume":"15","author":"E Tzolos","year":"2021","unstructured":"Tzolos E, McElhinney P, Williams MC, Cadet S, Dweck MR, Berman DS, Slomka PJ, Newby DE, Dey D. Repeatability of quantitative pericoronary adipose tissue attenuation and coronary plaque burden from coronary CT angiography. J Cardiovasc Comput. 2021;15(1):81\u20134.","journal-title":"J Cardiovasc Comput"},{"issue":"3","key":"2723_CR25","doi-asserted-by":"publisher","first-page":"null","DOI":"10.3390\/ijms25031700","volume":"25","author":"BB M\u00e1ty\u00e1s","year":"2024","unstructured":"M\u00e1ty\u00e1s BB, Benedek I, Ra\u021b N, Bl\u00eendu E, Parajk\u00f3 Z, Mih\u0103il\u0103 T, Benedek T. Assessing the impact of long-term high-dose statin treatment on pericoronary inflammation and plaque distribution\u2014a comprehensive coronary CTA follow-up study. Int J Mol Sci. 2024;25(3):null.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2723_CR26","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/oby.22798","volume":"28","author":"G Iacobellis","year":"2020","unstructured":"Iacobellis G, Gra-Menendez S. Effects of dapagliflozin on epicardial fat thickness in patients with type 2 diabetes and obesity. Obesity. 2020;28(6):1068\u201374.","journal-title":"Obesity"},{"issue":"2","key":"2723_CR27","doi-asserted-by":"publisher","first-page":"102213","DOI":"10.1016\/j.cpcardiol.2023.102213","volume":"49","author":"HE Mac\u00edas-Cervantes","year":"2024","unstructured":"Mac\u00edas-Cervantes HE, Mart\u00ednez-Ram\u00edrez DB, Hinojosa-Guti\u00e9rrez LR, C\u00f3rdova-Silva DA, Rios-Mu\u00f1oz JA. Effect of dapagliflozin on epicardial fat volume in patients with acute coronary syndrome assessed by computed tomography. Curr Prob Cardiol. 2024;49(2):102213.","journal-title":"Curr Prob Cardiol"},{"issue":"1","key":"2723_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12933-023-02091-0","volume":"22","author":"F Cinti","year":"2023","unstructured":"Cinti F, Leccisotti L, Sorice GP, Capece U, D\u2019Amario D, Lorusso M, Gugliandolo S, Morciano C, Guarneri A, Guzzardi MA, et al. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes. Cardiovasc Diabetol. 2023;22(1):349.","journal-title":"Cardiovasc Diabetol"},{"key":"2723_CR29","unstructured":"Chinese Diabetes Society. Chinese diabetes society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 Edition). Chin J Diabetes Mellitus 2021."},{"issue":"6","key":"2723_CR30","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.jcmg.2022.02.004","volume":"15","author":"E Tzolos","year":"2022","unstructured":"Tzolos E, Williams MC, McElhinney P, Lin A, Grodecki K, Flores Tomasino G, Cadet S, Kwiecinski J, Doris M, Adamson PD, et al. Pericoronary adipose tissue attenuation, low-attenuation plaque burden, and 5-year risk of myocardial infarction. Jacc-Cardiovasc Imag. 2022;15(6):1078\u201388.","journal-title":"Jacc-Cardiovasc Imag"},{"issue":"5","key":"2723_CR31","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jcmg.2021.10.014","volume":"15","author":"A Nakajima","year":"2022","unstructured":"Nakajima A, Sugiyama T, Araki M, Seegers LM, Dey D, McNulty I, Lee H, Yonetsu T, Yasui Y, Teng Y, et al. Plaque rupture, compared with plaque erosion, is associated with a higher level of Pancoronary inflammation. Jacc-Cardiovasc Imaging. 2022;15(5):828\u201339.","journal-title":"Jacc-Cardiovasc Imaging"},{"issue":"1","key":"2723_CR32","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s12933-024-02445-2","volume":"23","author":"Y Li","year":"2024","unstructured":"Li Y, Yao W, Wang T, Yang Q, Song K, Zhang F, Wang F, Dang Y. Association of semaglutide treatment with coronary artery inflammation in type 2 diabetes mellitus patients: a retrospective study based on pericoronary adipose tissue Attenuation. Cardiovasc Diabetol. 2024;23(1):348.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"2723_CR33","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.jcmg.2021.11.025","volume":"15","author":"N Nerlekar","year":"2022","unstructured":"Nerlekar N, Chan J. Pericoronary adipose tissue: another arrow in the quiver of CT coronary angiography. Jacc-Cardiovasc Imaging. 2022;15(5):840\u20132.","journal-title":"Jacc-Cardiovasc Imaging"},{"issue":"1","key":"2723_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12933-022-01478-9","volume":"21","author":"K Ichikawa","year":"2022","unstructured":"Ichikawa K, Miyoshi T, Osawa K, Nakashima M, Miki T, Nishihara T, Toda H, Yoshida M, Ito H. High pericoronary adipose tissue Attenuation on computed tomography angiography predicts cardiovascular events in patients with type 2 diabetes mellitus: post-hoc analysis from a prospective cohort study. Cardiovasc Diabetol. 2022;21(1):44.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2723_CR35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12933-024-02199-x","volume":"23","author":"Y Liu","year":"2024","unstructured":"Liu Y, Dai L, Dong Y, Ma C, Cheng P, Jiang C, Liao H, Li Y, Wang X, Xu X. Coronary inflammation based on pericoronary adipose tissue attenuation in type 2 diabetic mellitus: effect of diabetes management. Cardiovasc Diabetol. 2024;23(1):108.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2723_CR36","first-page":"327","volume":"16","author":"Y Yu","year":"2022","unstructured":"Yu Y, Ding X, Yu L, Dai X, Wang Y, Zhang J. Increased coronary pericoronary adipose tissue attenuation in diabetic patients compared to non-diabetic controls: a propensity score matching analysis. J Cardiovasc Comput. 2022;16(4):327\u201335.","journal-title":"J Cardiovasc Comput"},{"issue":"1","key":"2723_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12933-024-02272-5","volume":"23","author":"M Liu","year":"2024","unstructured":"Liu M, Zhen Y, Shang J, Dang Y, Zhang Q, Ni W, Qiao Y, Hou Y. The predictive value of lesion-specific pericoronary fat Attenuation index for major adverse cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2024;23(1):191.","journal-title":"Cardiovasc Diabetol"},{"issue":"10444","key":"2723_CR38","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/S0140-6736(24)00596-8","volume":"403","author":"K Chan","year":"2024","unstructured":"Chan K, Wahome E, Tsiachristas A, Antonopoulos AS, Patel P, Lyasheva M, Kingham L, West H, Oikonomou EK, Volpe L, et al. Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study. Lancet. 2024;403(10444):2606\u201318.","journal-title":"Lancet"},{"issue":"13","key":"2723_CR39","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.jacc.2024.06.002","volume":"84","author":"SM Hollenberg","year":"2024","unstructured":"Hollenberg SM, Stevenson LW, Ahmad T, Bozkurt B, Butler J, Davis LL, Drazner MH, Kirkpatrick JN, Morris AA, Page RL, et al. 2024 ACC expert consensus decision pathway on clinical assessment, management, and trajectory of patients hospitalized with heart failure focused update: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2024;84(13):1241\u201367.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2723_CR40","first-page":"148","volume":"40","author":"YH Li","year":"2024","unstructured":"Li YH, Wang CC, Hung CL, Wu YW, Hsu CH, Tsou YL, Wang CH, Wu CK, Lin PL, Chang HY, et al. 2024 guidelines of the Taiwan society of cardiology for the diagnosis and treatment of heart failure with preserved ejection fraction. Acta Cardiol Sin. 2024;40(2):148\u201371.","journal-title":"Acta Cardiol Sin"},{"issue":"4","key":"2723_CR41","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(4):422\u201334.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2723_CR42","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New Engl J Med. 2022;387(12):1089\u201398.","journal-title":"New Engl J Med"},{"key":"2723_CR43","doi-asserted-by":"crossref","unstructured":"Sridharan K, Sivaramakrishnan G. Sodium glucose Cotransporter-2 inhibitors improve endothelial function and arterial stiffness in diabetic individuals: a systematic review and network Meta-Analysis. Curr Vasc Pharmacol. 2025.","DOI":"10.2174\/0115701611337138241226101956"},{"issue":"11","key":"2723_CR44","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.7150\/thno.75121","volume":"12","author":"L Ma","year":"2022","unstructured":"Ma L, Zou R, Shi W, Zhou N, Chen S, Zhou H, Chen X, Wu Y. SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia\/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways. Theranostics. 2022;12(11):5034\u201350.","journal-title":"Theranostics"},{"issue":"1","key":"2723_CR45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12933-021-01264-z","volume":"20","author":"AC Sposito","year":"2021","unstructured":"Sposito AC, Breder I, Soares AAS, Kimura-Medorima ST, Munhoz DB, Cintra RMR, Bonilha I, Oliveira DC, Breder JC, Cavalcante P, et al. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovasc Diabetol. 2021;20(1):74.","journal-title":"Cardiovasc Diabetol"},{"key":"2723_CR46","doi-asserted-by":"crossref","unstructured":"Kounatidis D, Vallianou N, Evangelopoulos A, Vlahodimitris I, Grivakou E, Kotsi E, Dimitriou K, Skourtis A, Mourouzis I. SGLT-2 inhibitors and the inflammasome: what\u2019s next in the 21st century? Nutrients. 2023;15(10).","DOI":"10.3390\/nu15102294"},{"issue":"null","key":"2723_CR47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.vph.2018.06.006","volume":"109","author":"M El-Daly","year":"2018","unstructured":"El-Daly M, Pulakazhi Venu VK, Saifeddine M, Mihara K, Kang S, Fedak PWM, Alston LA, Hirota SA, Ding H, Triggle CR, et al. Hyperglycaemic impairment of PAR2-mediated vasodilation: prevention by Inhibition of aortic endothelial sodium-glucose-co-transporter-2 and minimizing oxidative stress. Vasc Pharmacol. 2018;109(null):56\u201371.","journal-title":"Vasc Pharmacol"},{"issue":"1","key":"2723_CR48","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12933-024-02481-y","volume":"23","author":"FR Alsereidi","year":"2024","unstructured":"Alsereidi FR, Khashim Z, Marzook H, Al-Rawi AM, Salomon T, Almansoori MK, Madkour MM, Hamam AM, Ramadan MM, Peterson QP, et al. Dapagliflozin mitigates cellular stress and inflammation through PI3K\/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived \u0392 cells. Cardiovasc Diabetol. 2024;23(1):388.","journal-title":"Cardiovasc Diabetol"},{"key":"2723_CR49","doi-asserted-by":"crossref","unstructured":"Goedeke L, Ma Y, Gaspar RC, Nasiri A, Lee J, Zhang D, Galsgaard KD, Hu X, Zhang J, Guerrera N et al. SGLT2 Inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts. J Clin Invest. 2024;134(24).","DOI":"10.1172\/JCI176708"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02723-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02723-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02723-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T12:02:46Z","timestamp":1744977766000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02723-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2723"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02723-7","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"25 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the Ethics Review Committee of Hebei Provincial People\u2019s Hospital (No. 2025-LW-0019) and was conducted in accordance with the principles outlined in the Declaration of Helsinki. However, because this was a retrospective study, patient informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}